Company research / ENVB

Enveric Biosciences, Inc. (ENVB)

CIK 0000890821 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Key ratios (year ended 2025-12-31)

-210.0%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-14

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-25, first reflected in a filing dated 2020-03-25; 1-for-12, first reflected in a filing dated 2025-11-14. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenuen/an/an/an/an/an/an/a$39.91M$43.00M$48.59M$36.15M
Cost of Revenuen/an/an/an/an/an/an/a$31.76M$34.01M$38.36M$29.22M
Gross Profitn/an/an/an/an/an/an/a$8.15M$8.98M$10.24M$6.93M
R&D Expense$2.48M$2.78M$2.84M$7.25M$8.03M$4.79M$174.1Kn/an/an/a$55.1K
Operating Income-$8.73M-$8.77M-$9.63M-$16.45M-$27.42M-$64.62M-$5.62M-$2.30M-$7.15M-$10.90M-$5.38M
Depreciation & Amortization$153.9K$200.9K$337.5K$344.0K$327.9K$656.6K$120.9K$2.27M$2.90M$3.22M$1.36M
EBITDA-$8.57M-$8.57M-$9.29M-$16.10M-$27.09M-$63.97M-$5.50M-$31.2K-$4.24M-$7.68M-$4.02M
Net Income-$8.73M-$8.77M-$9.57M-$17.29M-$18.47M-$48.98M-$6.86M-$2.41M-$16.90M-$9.07M-$2.78M
EPS (Diluted)n/a-$36.24-$228.48-$121.29-$13.00n/an/a-$2.83-$20.47-$0.75-$0.21
Total Assets$8.94M$5.10M$3.08M$4.30M$19.55M$26.72M$4.10M$108.8K$29.64M$52.20M$39.51M
Total Liabilitiesn/an/an/an/a$4.00M$4.41M$681.2K$1.92M$18.88M$32.75M$27.84M
Long-Term Debtn/an/an/an/an/an/an/a$740.3K$6.5K$1.88M$1.94M
Shareholders' Equity$8.08M$4.18M$1.59M$1.96M$14.67M$22.31M$3.42M-$1.81M$10.76M$19.45M$11.66M
Cash & Equivalentsn/an/an/an/an/an/an/a$431.4K$1.37M$4.88M$1.38M
Operating Cash Flow-$8.56M-$8.14M-$7.73M-$14.09M-$17.15M-$11.46M-$3.89M-$647.9K-$2.57M-$2.74M-$2.70M
Capital Expendituresn/an/an/a$5.2K$584.2K$189.7Kn/an/an/an/an/a
Free Cash Flown/an/an/a-$14.10M-$17.73M-$11.65Mn/an/an/an/an/a
Shares Outstanding3.94M1.06M56.5K182.6K2.08M651.9K10.10M5.31M1.69M18.16M13.89M
Weighted Average Diluted Sharesn/a334.7K41.9K143.9K1.45Mn/an/a2.13M951.6K14.98M13.07M
EPS (Basic)n/a-$36.24-$228.48-$121.29-$13.00-$103.69n/a-$2.83-$20.47-$0.75-$0.21

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView